Diosmin induces genotoxicity and apoptosis in DU145 prostate cancer cell line

Anna Lewinska1, Justyna Siwak2, Iwona Rzeszutek2

  • 1Department of Biochemistry and Cell Biology, University of Rzeszow, Zelwerowicza 4, 35-601 Rzeszow, Poland.

Insights

Dietary flavonoids like diosmin can induce cancer cell death through genotoxicity, promoting DNA damage and apoptosis. This study highlights diosmin

Area of Science:

  • * Nutritional biochemistry
  • * Molecular oncology

Background:

  • * Plant-derived polyphenols, especially flavonoids, show promise as anticancer agents due to their pro-apoptotic and chemopreventive properties.
  • * The potential for flavonoid-induced genotoxicity to trigger cancer cell death warrants investigation.

Purpose of the Study:

  • * To investigate the cyto- and genotoxicity of naringin, diosmin, and hesperidin in DU145 prostate cancer cells.
  • * To determine if flavonoid-induced genotoxicity contributes to cancer cell death.

Main Methods:

  • * Cytotoxicity and genotoxicity assays on DU145 cells treated with flavonoid glycosides.
  • * Measurement of reactive oxygen species (ROS) and superoxide production.
  • * Assessment of DNA double-strand breaks (DSBs) and micronuclei formation.
  • * Analysis of 53BP1 recruitment and DNA/chromosomal damage.
  • * Evaluation of DNA hypomethylation and epigenetic modulation.

Main Results:

  • * Flavonoid glycosides reduced cancer cell number and proliferation.
  • * Treatment increased intracellular ROS and superoxide levels.
  • * Flavonoids induced DSBs and micronuclei production, with diosmin being the most potent genotoxic agent.
  • * Diosmin exhibited pro-apoptotic activity, linked to its genotoxicity.
  • * Naringin and hesperidin showed less DNA damage compared to diosmin.
  • * Flavonoids acted as DNA hypomethylating agents, altering gene expression.

Conclusions:

  • * Diosmin, a dietary flavonoid glycoside, demonstrates anticancer activity against DU145 cells by inducing genotoxicity and apoptosis.
  • * Flavonoid-induced genotoxicity is a mechanism contributing to cancer cell death.
  • * Further in vitro and in vivo studies on diosmin's biological activity against cancer cells are recommended.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.4K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
74